February 2, 2021 11:29 AM EST

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

James Sabry and Aviv Regev at Roche and Genentech have been racking up early stage partnerships, tying up with early stage biotechs developing everything from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

Editor

Sign up to read this article for free.

more like this

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6